33 results about "EBV Infections" patented technology

The present invention provides cytotoxic Epstein-Barr virus (EBV) T-cell epitopes derived from EBV structural antigens. Preferred epitopes include YLLEMLWRL (SEQ ID NO:1), YFLEILWGL (SEQ ID NO:32), YLLEILWRL (SEQ ID NO:33), YLQQNWWTL (SEQ ID NO:6), LLLALLFWL (SEQ ID NO:2), LLVDLLWLL (SEQ ID NO:3), LLLIALWNL (SEQ ID NO:4), WLLLFLAIL (SEQ ID NO:5), TLLVDLLWL (SEQ ID NO:7), LLWLLLFLA (SEQ ID NO:8), ILLIIALYL (SEQ ID NO:9), VLFIFGCLL (SEQ ID NO:10), RLGATIWQL (SEQ ID NO:11), ILYFIAFAL (SEQ ID NO:15), SLVIVTTFV (SEQ ID NO:17), LMIIPLINV (SEQ ID NO:20), TLFIGSHVV (SEQ ID NO:24), LIPETVPYI (SEQ ID NO:26), VLQWASLAV (SEQ ID NO:27) and QLTPHTKAV (SEQ ID NO:29). The present invention also provides methods of treating or preventing EBV infection in subjects which involve administration of EBV cytotoxic T-cell epitopes.

The present invention relates to the identification of a subunit vaccine to prevent or treat infection of Epstein Barr Virus. In particular, EBNA-1 was identified as a vaccine antigen. In a specific embodiment, a purified protein corresponding to EBNA-1 elicited a strong CD4+ T cell response. The responsive CD4+ T cell are primarily TH1 in function. EBNA-1 is an attractive candidate for a protective vaccine against EBV, and for immunotherapy of EBV infection and neoplasms, particularly with dendritic cells charged with EBNA-1.

The invention provides a herpes virus EBV (Epstein-Barr Virus) detection kit. The kit comprises a nucleic acid releasing agent and PCR (polymerase chain reaction) reaction solution, wherein the nucleic acid releasing agent comprises 0.01-0.5 mM / L of surfactin, 20-300 mM / L of potassium chloride, 0.01-2% of sodium dodecyl sulphate and 0.05-1% of ethanol; and the PCR reaction solution comprises an upstream primer and a downstream primer used for target polynucleotide amplification, and a probe used for target polynucleotide detection. The detection result of the method for releasing nucleic acid by the nucleic acid releasing agent in the kit disclosed by the invention has no obvious difference with the detection result of a boiling method, a strong protein denaturing agent is used during nucleic acid extraction in the kit disclosed by the invention for rapidly breaking the coat protein structure of a pathogen and releasing the nucleic acid of the pathogen, and release and extraction for DNA (deoxyribonucleic acid) can be rapidly finished without heating; the sensitivity of the EBV detection of the kit disclosed by the invention can achieve 400 copies / ml, and the quantitative linear range is 400-4.00E+09 copies / ml; by applying the kit, rapid and accurate detection can be performed on EBV-DNA in the unknown samples of blood plasma, throat swab, peripheral blood and the like, and reliable experimental basis is provided for diagnosing EBV infection.

The invention discloses a molecular target hsa-miR203 for diagnosing and treating nasopharyngeal cancer related with Epstein-Barr virus (EBV) infection and application thereof. The microRNA can accurately reflect the conditions of retention and loss of EBV viruses in cells and tissues, and further can be used for diagnosing the nasopharyngeal cancer related with the EBV infection; and meanwhile, target genes E2F3, CCNG1 and the like controlled by the hsa-miR203 obviously inhibit the proliferation and conversion capacities of the cells, so the hsa-miR203 can be used for treating the nasopharyngeal cancer related with the EBV infection. Therefore, the hsa-miR203 has important scientific research theory and clinical application value, and provides new clue and proof for diagnosis, treatment or prognosis of EBV related tumors.

The present invention provides a cytotoxic T-cell (cytotoxic T lymphocyte, abbreviated hereinafter as CTL) epitope peptide specific to the Epstein-Barr virus (described hereinafter as EBV), a vaccinefor treating or preventing EBV infection or EBV-positive cancer using this peptide, a passive immunotherapeutic agent for EBV, and a method for assaying CTL specific to EBV. The present invention alsoprovides an HLA-A*24:02-restricted epitope peptide comprising an IYTEVRELV sequence (SEQ ID NO: 43) from a cytoskeleton-associated protein (cytoskeleton-associated protein 4: CKAP4 hereinafter, alsoknown as: CLIMP-63, ERGIC-63, P63). The peptide-specific cytotoxic T-cells (CTL hereinafter) can attack malignant tumor cells that express a high level of CKAP4.

The invention discloses a euphorbia splendens extract. The structure formula of the euphorbia splendens extract is expressed as formula (I), wherein R1 and R2 are cyclized to form cyclohexene or phenyl; any one or more hydrogen groups on cyclohexene or phenyl are substituted by R4; R4 is selected from hydrogen, hydroxyl, carbonyl, C1-C5 alcohol group or C1-C5 alkyl; or R4 and carbon on cyclohexene or phenyl form carbonyl; R3 is hydrogen, hydroxyl or carbonyl. The euphorbia splendens extract provided by the invention has obvious inhibition effect on lytic replication split period of EBV, is relatively low in toxicity to host cells, has certain safety and can be used for preparing drugs for preventing and treating EBV infection. The formula (I) is shown in the description.

The invention relates to a cell line, and specifically relates to a NK / T cell line of the human. The conservation number is CGMCC No. 14892. The NK / T cell line of the human provided by the invention can be passaged for a long time and greatly amplified, and has stronger anti-tumor activity, and provides a new experimental model for deeply development chronic activity EBV infectious disease mechanism research, screening chronic activity EBV infection, diagnosis molecular marker of EBV related lymphocytosis and the like, treating prognosis maker and treatment medicine, CD8+T cell, natural killercell anti-tumor action mechanism and clinic adoptive immunity treatment for a researcher.

The invention relates to the cell line, and specifically relates to a NK cell line of the human. The conservation number is CGMCC No. 14891. The NK cell line of the human provided by the invention canbe passaged for a long time and greatly amplified, and has stronger anti-tumor activity, and provides a new experimental model for deeply development chronic activity EBV infectious disease mechanismresearch, screening chronic activity EBV infection, treatment medicine of EBV related lymphocytosis and the like, natural killer cell anti-tumor action mechanism and clinic adoptive immunity treatment for a researcher.

Anti-Epstein Barr Virus (EBV) antibodies and vaccines are described herein. The antibodies and vaccines can be used to treat and / or reduce the risk of EBV infection and to treat and / or reduce the risk of complications associated with EBV infection, such as infectious mononucleosis, lymphoproliferative disorders, carcinomas, and smooth muscle tumors.

The invention discloses a high-throughput sequencing assay method for Epstein-Barr virus (EBV) integration assay. The method utilizes the genome information of the Epstein-Barr virus (EBV) in combination with the second-generation high-throughput sequencing technology to more comprehensively assay the condition of EBV infection of a patient, overcoming the defects of conventional assay methods, such as low accuracy, high false positive and poor repetitiveness. The adoption of gene sequencing can help increasing accuracy, and compared with the classical Sanger sequencing method mostly adopted at present, the assay method has the advantages of higher assay throughput, higher accuracy, lower cost, richer information and the like. With the help of the second-generation high-throughput sequencing technology, the assay method can carry out high-precision assay on the human infection of the Epstein-Barr virus, so that specific treatment can be carried out at the infection stage to reduce theharm of the disease on the human body, and thereby the occurrence of tumor is decreased.

The invention relates to a kit and a method for detecting EBV infection in a trace biological sample of an eye, and relates to a molecular detection technology for eye viral infections, in particularto a method for extracting DNA from the trace biological sample, wherein the trace biological sample refers to a liquid sample with a volume not exceeding 10mu l-200mu l or a solid sample with a volume not exceeding 1mm<3>. By use of the extracted DNA as a PCR detection template, the eye viral infections can be detected with an accuracy of more than 80%, and the method provides a reliable basis for subsequent appropriate treatment methods and reduces the blindness of the treatment methods.

Provided is a composition comprising an Epstein-Barr virus microRNA inhibitor for treating Epstein-Barr virus infection, and a method using Epstein-Barr virus microRNA for screening a therapeutic agent for treating Epstein-Barr virus infection. The provided composition enables one to induce the lytic cycle of EBV such that EBV-infected cells are destroyed by a host immune system. Therefore, the composition can be effectively used for the prevention or treatment of diseases, including various cancers, caused by EBV infection. Moreover, the provided method enables one to screen a therapeutic agent having excellent antiviral effect for treating Epstein-Barr virus infection by inducing Epstein-Barr virus lytic cycle.

The invention relates, in certain aspects, to developable forms of certain compounds that are useful to treat and / or prevent EBV infection and related conditions in a subject. The invention further provides EBNA1 inhibitors, and / or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and / or lytic EBV infection.

The invention relates to a double-target chimeric antigen receptor (CAR) capable of targeting LMP1 and GP350 simultaneously. The double-target CAR comprises a light chain of an anti-GP350 single-chainantibody, a heavy chain of the anti-GP350 single-chain antibody, a light chain of an anti-LMP1 single-chain antibody, a heavy chain of the anti-LMP1 single-chain antibody, a CD8[alpha] hinge region,a CD28 transmembrane region and intracellular region, a 4-1BB intracellular region and a CD3[zeta] intracellular region. The double-target CAR has higher specificity and safety, and has a specific killing effect on malignant tumors caused by EBV infection and EBV in a latent period.

The invention discloses a probe used for EBV detection and a detection method. Two rounds of PCR reaction are needed in the probe preparation process. The detection method based on an NGS technology comprises the following steps: preparing a DNA template, fragmenting genome DNA, purifying a fragmented product, constructing an introduction group library, carrying out PCR amplification on the genomelibrary, hybridizing a probe with the genome library, allowing magnetic beads to capture a hybridization product, carrying out high-throughput sequencing on an obtained captured product, and analyzing the EBV infection condition in a to-be-detected sample. The probe and the method disclosed by the invention have the advantages of low cost, fast data analysis, high coverage depth, high detection accuracy and the like, are applicable to early screening and postoperative diagnosis of diseases caused by EBV, and provide a guidance for personalized medication.

The invention provides an EBER probe for detecting EBV infected tissues and a detection kit, and belongs to the technical field of virus detection. The EBER probe is a fluorescein-labeled EBER probe, and the nucleotide sequence of the EBER probe is shown in SEQ ID NO: 1. The probe hybridization solution is an aqueous solution containing 10-20 pmol / [mu]l of an EBER probe, 50% of formamide, 10% of dextran sulfate, 1.0% of Triton X-100 and 50 mmol / L of Tris-HCl. The invention also provides the detection kit which comprises the probe hybridization solution, a DAPI counterstaining agent and a quality control sheet group, can realize the detection of the EBER state in a tissue or cell sample, and assists in clinically judging whether EBV infection exists or not. Through verification, the kit is high in detection sensitivity and good in specificity, the detection method is simple and convenient, the defects of an existing product or method are overcome, and the kit has wide application prospects.

The invention discloses a method for establishing an EBV (Epstein-Barr Virus) infected artificial respiratory tract epithelium model. The method comprises the following steps: (1) digesting nasopharyngeal mucosa tissues by using Dispase II, performing beating into single cells, and performing centrifuging to remove supernate, so as to obtain cell precipitate; (2) suspending and culturing the cellprecipitate by using an epithelial cell culture medium; (3) performing digesting into single cells, planting the single cells in a small chamber above the 24-hole support membrane, and performing culturing until the support membrane is overgrown; (4) completely removing the culture solution above the support membrane, and continuously culturing for 2-3 weeks; and (5) when large-area cilium swinging is observed, adding Akata cells to carry out cell contact mediated EBV infection, and when successful infection, obtaining the artificial respiratory tract epithelium model infected with the EBV. According to the establishing method, nasopharyngeal mucosa tissue is taken as a material part, nasopharyngeal epithelial cells can be differentiated into completely polarized pseudo-multilayer respiratory tract epithelial tissue through gas-liquid interface culture, and the nasopharyngeal epithelial tissue is completely simulated by basal layer cells, secretory cuppy cells and swinging cilium cells.

The invention provides a herpes virus EBV (Epstein-Barr Virus) detection kit. The kit comprises a nucleic acid releasing agent and PCR (polymerase chain reaction) reaction solution, wherein the nucleic acid releasing agent comprises 0.01-0.5 mM / L of surfactin, 20-300 mM / L of potassium chloride, 0.01-2% of sodium dodecyl sulphate and 0.05-1% of ethanol; and the PCR reaction solution comprises an upstream primer and a downstream primer used for target polynucleotide amplification, and a probe used for target polynucleotide detection. The detection result of the method for releasing nucleic acid by the nucleic acid releasing agent in the kit disclosed by the invention has no obvious difference with the detection result of a boiling method, a strong protein denaturing agent is used during nucleic acid extraction in the kit disclosed by the invention for rapidly breaking the coat protein structure of a pathogen and releasing the nucleic acid of the pathogen, and release and extraction for DNA (deoxyribonucleic acid) can be rapidly finished without heating; the sensitivity of the EBV detection of the kit disclosed by the invention can achieve 400 copies / ml, and the quantitative linear range is 400-4.00E+09 copies / ml; by applying the kit, rapid and accurate detection can be performed on EBV-DNA in the unknown samples of blood plasma, throat swab, peripheral blood and the like, and reliable experimental basis is provided for diagnosing EBV infection.

The present invention discloses an antibody against Epstein-Barr virus for the first time, which is composed of a light chain and a heavy chain. The heavy chain variable region of the heavy chain has three complementary regions CDR1, CDR2 and CDR3, and their amino acid sequences are respectively shown in SEQ ID NO .1-3, the light chain variable region of the light chain has 3 complementary regions CDR1', CDR2' and CDR3', the amino acid sequences of which are respectively as SEQ ID NO.4, GNN, SEQ ID NO.5 shown. The antibody can block EBV infection of B cells with an IC50 of 203ng / ml, but has no neutralizing effect on Ebola virus infection, indicating that the antibody has a high ability to specifically neutralize EBV infection of B cells.

The invention belongs to the field of medical science, and particularly discloses a method for differential diagnosis of EBV infected cell subtypes and application thereof, and the method comprises the following steps: staining cells by using a fluorescence labeled lymphocyte specific antibody, specifically recognizing EBV infection characteristic RNA: EBERs in the cells by using a FISH probe, and then detecting EBV infected cell subgroups by flow cytometry, the cell subtype infected by the EBV is identified. The flow cytometry and the in-situ fluorescence hybridization are combined for use, a method capable of directly, quickly, conveniently and reliably detecting and identifying the EBV infected cell subtype of lymphocytes in a clinical peripheral blood sample is established, and the method has extremely high clinical application value.

The invention provides EBNA1 inhibitors, and pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and / or rheumatoid arthritis. The compounds and compositions of the invention are further useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. The compounds and compositions of the invention are further useful for the treatment of diseases caused by lytic EBV infection.

The invention discloses an EBV (Epstein-Barr Virus) vaccine based on a vesicular stomatitis virus as well as a preparation method and application of the EBV vaccine. EBV key glycoproteins gB and gHgL are displayed on the surface of VSV for the first time, the modified VSV is used for animal immunization, a new EBV vaccine variety is provided, an organism is expected to be induced to generate strong enough immune response to prevent EBV from infecting host cells, and therefore the morbidity of EBV-related neoplastic and non-neoplastic diseases is reduced. Detection finds that the modified VSV can induce obvious specific antibodies aiming at EBV surface glycoproteins gB and gHgL; in addition, it is proved that the generated specific antibody can inhibit EBV from infecting epithelial cells and B lymphocytes; the invention also shows that the EBV vaccine based on the VSV can be used for preventing and controlling EBV infection of people and related neoplastic and non-neoplastic diseases and has a good immune effect.

The invention discloses a euphorbia splendens extract. The structure formula of the euphorbia splendens extract is expressed as formula (I), wherein R1 and R2 are cyclized to form cyclohexene or phenyl; any one or more hydrogen groups on cyclohexene or phenyl are substituted by R4; R4 is selected from hydrogen, hydroxyl, carbonyl, C1-C5 alcohol group or C1-C5 alkyl; or R4 and carbon on cyclohexene or phenyl form carbonyl; R3 is hydrogen, hydroxyl or carbonyl. The euphorbia splendens extract provided by the invention has obvious inhibition effect on lytic replication split period of EBV, is relatively low in toxicity to host cells, has certain safety and can be used for preparing drugs for preventing and treating EBV infection. The formula (I) is shown in the description.